In vitro inhibition of<i>Helicobacter pylori</i>by<i>Enterococcus faecium</i>GM-1

Kang, J.H.; Lee, M S

doi:10.1139/w05-044

Cited by 9 publications

(5 citation statements)

References 32 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, several studies have found that SCS from LAB exhibit antibacterial activity against H. pylori both in vitro and in vivo 15–18, 41. It has been reported that lactic acid and other potentially inhibitory metabolites such as acetic acid, formic acid and proteins in fermented milk or culture supernatant fractions have a direct effect on pathogens 18, 20, 22, 28, 42–44.…”

Section: Discussionmentioning

confidence: 99%

Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria

Lin

Fang

et al. 2011

J. Sci. Food Agric.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria

Lin

Fang

et al. 2011

J. Sci. Food Agric.

View full text Add to dashboard Cite

show abstract

“…Researchers have found that a 1% solution of lactic acid (about 100 mmol/L) was sufficient to inhibit the growth and urease activity of H. pylori (Bhatia and others 1989; Aiba and others 1998). Recently, several studies have reported that SCS from lactic acid bacteria exhibits antibacterial activity against H. pylori (Michetti and others 1999; Kang and Lee 2005). It has been demonstrated that the coccoid form of H. pylori results in a loss of infectivity (Kusters and others 1997; Enroth and others 1999).…”

Section: Discussionmentioning

confidence: 99%

Antagonistic Activity of Spent Culture Supernatants of Lactic Acid Bacteria against Helicobacter Pylori Growth and Infection in Human Gastric Epithelial AGS Cells

Lin¹,

Lin²,

Sheu³

et al. 2009

Journal of Food Science

View full text Add to dashboard Cite

We investigated the bactericidal activity and exclusion effect of 10 strains of lactic acid bacteria (LAB) isolated from different commercial food products and infant feces against Helicobacter pylori (H. pylori) in human gastric epithelial AGS cells. Antagonistic activity of spent culture supernatants (SCS) from LAB (LAB-SCS) was tested, and the content of organic acids in SCS was analyzed with high-performance liquid chromatography (HPLC). In addition, the bactericidal activities of LAB-SCS were estimated by a time-kill assay and by measuring the exclusion effect of LAB-SCS against H. pylori in AGS cells. The results showed that SCS from certain strains with higher concentrations of organic acids dramatically decreased the viability of H. pylori. We also proved that the organic acids could inhibit H. pylori adhesion and invasion of AGS cells. Furthermore, the concentration and speciation of organic acids in SCS after fermentation of LAB are important factors in the inhibition of H. pylori infection. In addition, the in vitro methods used in this study might provide for the rapid screening of potential probiotics with anti-H. pylori activity in the dairy industry.

show abstract

“…The mechanisms through which probiotics can antagonise H. pylori include inhibition of H. pylori growth by secreting antibacterial substances or by hindering the activity of urease enzyme and reduction of H. pylori infectivity by reducing its ability to adhere to gastric epithelial cells, by strengthening mucosal barrier, and by regulating immune and inflammatory responses of the host (Fig. 1) [22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold

Compare

Sgamato

Nardone

et al. 2021

Dig Dis

View full text Add to dashboard Cite

Background: Multiple lines of evidence now support the notion that gut microbiota can contribute to digestive and extra-digestive diseases. The emergence of these observations enabled to postulate a bacteria-centric paradigm upon which to rethink the treatment of many diseases. The goal of therapy should not be to eradicate the flora but to modify it in a way that leads to symptomatic improvement; thus, the interest in the use of probiotics to modulate microbiota composition has increased worldwide in both community and healthcare settings. Summary: The results of published studies are conflicting for most probiotic strains and formulations, and clinicians and consumers need a better understanding of probiotic risks and benefits. Currently, clear guidelines on when to use probiotics and the most effective probiotic for different gastrointestinal conditions are still lacking. Here we reviewed the studies on the use of probiotics in some diseases of relevant interest to gastroenterologists, such as Helicobacter pylori infection, irritable bowel syndrome, and inflammatory bowel disease. Key message: Although the evidence is relevant and promising for probiotics in general, and for specific strains and combinations of strains, it is not yet sufficient to draw unequivocal conclusions and clear recommendations.

show abstract

In vitro inhibition ofHelicobacter pyloribyEnterococcus faeciumGM-1

Cited by 9 publications

References 32 publications

Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria

Anti-Helicobacter pylori activity of fermented milk with lactic acid bacteria

Antagonistic Activity of Spent Culture Supernatants of Lactic Acid Bacteria against Helicobacter Pylori Growth and Infection in Human Gastric Epithelial AGS Cells

Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold

Contact Info

Product

Resources

About